Abstract
Pediatric brainstem gliomas often harbor oncogenic K27M mutation of histone H3.3. Here we show that GSKJ4 pharmacologic inhibition of K27 demethylase JMJD3 increases cellular H3K27 methylation in K27M tumor cells and demonstrate potent antitumor activity both in vitro against K27M cells and in vivo against K27M xenografts. Our results demonstrate that increasing H3K27 methylation by inhibiting K27 demethylase is a valid therapeutic strategy for treating K27M-expressing brainstem glioma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Wu, G. et al. Nat. Genet. 44, 251–253 (2012).
Schwartzentruber, J. et al. Nature 482, 226–231 (2012).
Chan, K.M. et al. Genes Dev. 27, 985–990 (2013).
Lewis, P.W. et al. Science 340, 857–861 (2013).
Bender, S. et al. Cancer Cell 24, 660–672 (2013).
Venneti, S. et al. Brain Pathol. 23, 558–564 (2013).
Grimm, S.A. & Chamberlain, M.C. Curr. Neurol. Neurosci. Rep. 13, 346 (2013).
Hashizume, R. et al. J. Neurooncol. 110, 305–313 (2012).
Mueller, S. et al. Neuro-oncol. 16, 352–360 (2014).
Cao, R. et al. Science 298, 1039–1043 (2002).
Lund, A.H. & van Lohuizen, M. Curr. Opin. Cell Biol. 16, 239–246 (2004).
Agger, K. et al. Nature 449, 731–734 (2007).
Kruidenier, L. et al. Nature 488, 404–408 (2012).
McCabe, M.T. et al. Nature 492, 108–112 (2012).
Aoki, Y. et al. J. Neurooncol. 108, 29–35 (2012).
Sarkaria, J.N. et al. Clin. Cancer Res. 12, 2264–2271 (2006).
Bjerke, L. et al. Cancer Discov. 3, 512–519 (2013).
Langmead, B. & Salzberg, S.L. Nat. Methods 9, 357–359 (2012).
Kharchenko, P.V., Tolstorukov, M.Y. & Park, P.J. Nat. Biotechnol. 26, 1351–1359 (2008).
Zhu, L.J. et al. BMC Bioinformatics 11, 237 (2010).
Acknowledgements
Supported by US National Institutes of Health (NIH) Brain Tumor SPORE grant CA97257 (R.H., C.D.J.), the Pediatric Brain Tumor Foundation (R.H., N.G., C.D.J.), the Matthew Larson Foundation (R.H.), the Bear Necessities Pediatric Cancer Foundation (R.H.) and Rally Foundation (R.H.), American Cancer Society IRG-97-150-13 (R.H.), NIH CA157489 (Z.Z.), the Childhood Brain Tumor Foundation (C.P.), the Voices Against Brain Tumor Foundation (C.P.) and NIH CA164746 (C.P.).
Author information
Authors and Affiliations
Contributions
R.H. designed and conducted all of the experiments and wrote the manuscript. N.A. performed bioinformatics analysis for the data from gene expression and ChIP-seq. Y.I. performed the in vitro studies and provided valuable discussion. R.L. performed the cell cycle analysis, flow cytometry analysis and quantitative RT-PCR. H.G., X.C. and D.F. performed the ChIP-seq experiments. X.H. provided valuable discussion and intellectual input. M.W.T. performed the in vitro studies. V.N. performed microarray analysis. D.S. provided valuable material and intellectual input. S.M. provided clinical information and conceptual advice. P.L.P. supervised microarray analysis and provided valuable discussion and intellectual input. Z.Z. supervised ChIP-seq experiments and provided valuable discussion. C.P. supervised the in vitro experiments and provided valuable discussion and intellectual input. N.G. provided clinical information and supervised the projects. T.A.W. provided valuable discussion and intellectual input and edited the manuscript. C.D.J. supervised the projects, provided valuable discussion and conceptual advice and edited the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–11 and Supplementary Tables 1–3 (PDF 7557 kb)
Rights and permissions
About this article
Cite this article
Hashizume, R., Andor, N., Ihara, Y. et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med 20, 1394–1396 (2014). https://doi.org/10.1038/nm.3716
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3716
This article is cited by
-
PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo
Scientific Reports (2024)
-
Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways
Acta Neuropathologica Communications (2023)
-
Targeting the epigenome of cancer stem cells in pediatric nervous system tumors
Molecular and Cellular Biochemistry (2023)
-
Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes
Scientific Reports (2023)
-
Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics
Cancer Imaging (2022)